Pharmaceutical manufacturing is entering a faster regulatory era. FDA is testing accelerated review models, companies are investing in artificial intelligence, and manufacturers are reconsidering where critical products should be produced. However, FDA’s latest quality data reveal an uncomfortable reality: faster
